This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Journal Club
Clinical Paper of the Month - Ab-externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 1-year Results from a 2-year Randomized, Multicenter Study
Ab-externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 1-year Results from a 2-year Randomized, Multicenter Study

Publishing date: June 2021

Author(s): N Douglas Baker (1), Howard S Barnebey (2), Marlene R Moster (3), Michael C Stiles (4), Steven D Vold (5), Anup K Khatana (6), Brian E Flowers (7), Davinder S Grover (8), Nicholas G Strouthidis (9), Joseph F Panarelli (10), INN005 study group

1 Ophthalmic Surgeons and Consultants of Ohio, Columbus, OH, USA.
2 Specialty Eyecare Centre, Bellevue, WA, USA.
3 Wills Eye Hospital, Philadelphia, PA, USA.
4 Stiles Eyecare Excellence, Overland Park, KS, USA.
5 Vold Vision, Fayetteville, AR, USA.
6 Cincinnati Eye Institute, Cincinnati, OH, USA.
7 Ophthalmology Associates, Fort Worth, TX, USA.
8 Glaucoma Associates of Texas, Dallas, TX, USA.
9 NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, NSW, Australia.
10 New York University, New York, NY, USA. Electronic address: joseph.panarelli@nyulangone.org.

OBJECTIVE: To compare the effectiveness and safety of the MicroShunt versus trabeculectomy in patients with primary open-angle glaucoma (POAG).

DESIGN: One-year results from a 2-year, prospective, randomized, multicenter, non-inferiority study (NCT01881425) conducted in the USA and Europe.

PARTICIPANTS: Eligible patients were aged 40-85 years with intraocular pressure (IOP) ≥15 and ≤40 mmHg and mild-to-severe POAG inadequately controlled on maximum tolerated medical therapy.

INTERVENTION: Patients were randomized 3:1 to undergo stand-alone MicroShunt implantation or trabeculectomy, both performed with adjunctive Mitomycin C (0.2 mg/mL for 2 minutes).

MAIN OUTCOME MEASURES: The primary effectiveness endpoint was surgical success, defined as ≥20% reduction in mean diurnal IOP from baseline (no medication washout) at year 1 without increasing the number of glaucoma medications. Secondary effectiveness endpoints at year 1 were the mean IOP change from baseline and requirement for postoperative intervention. Additional endpoints included glaucoma medication use and adverse events.

RESULTS: Overall, 395 (MicroShunt) and 132 (trabeculectomy) patients were randomized (mean Humphrey visual field mean deviation -12.34 dB). At year 1, probability of success was lower in the MicroShunt group compared with the trabeculectomy group (53.9% versus 72.7%, respectively; P<0.01). In the MicroShunt group, mean IOP ± standard deviation decreased from 21.1±4.9 mmHg at baseline to 14.3±4.3 mmHg (-29.1%; P<0.01) at year 1, with a mean of 0.6±1.1 glaucoma medications (baseline 3.1±1.0; P<0.01). In the trabeculectomy group, mean IOP decreased from 21.1±5.0 mmHg to 11.1±4.3 mmHg (-45.4%; P<0.01), with a mean of 0.3±0.9 glaucoma medications (baseline 3.0±0.9; P<0.01). Postoperative interventions, including laser suture lysis, were reported in 40.8% (MicroShunt) versus 67.4% (trabeculectomy) of patients (P<0.01). Reported incidence of transient hypotony was higher in the trabeculectomy group versus the MicroShunt group (49.6% versus 28.9%; P<0.01). Vision-threatening complications were uncommon and reported in 1.0% of MicroShunt versus 0.8% of trabeculectomy patients.

CONCLUSIONS: Probability of success was lower with MicroShunt compared with trabeculectomy. Though reductions in IOP and glaucoma medications over 1 year were observed in both groups, the trabeculectomy group had a lower mean IOP on fewer medications.

Copyright © 2021. Published by Elsevier Inc.

Ophthalmology. 2021 May 26;S0161-6420(21)00384-5. doi: 10.1016/j.ophtha.2021.05.023.

PMID: 34051211



Clinical Paper of the Month manager: Anthony Khawaja
Editorial Board: Humma Shahid, Karl Mercieca, Francisco Goni
Editors in Chief: Francesco Oddone, Manuele Michelessi




back to top

X